Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.
The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.
Editas has paid $1 million to test-drive Adverum's viral vectors in clinical gene editing and $1 million for an option on an exclusive license.
The Massachusetts-based clinical gene editing firm has obtained exclusive rights to use the engineered Cas9 variants developed by one of its co-founders.
The deal sets up a multi-year collaboration on hematopoietic stem cell and T-cell editing with the San Raffaele Telethon Institute for Gene Therapy.
CFFT will support drug discovery and development for cystic fibrosis while Editas will look into both common and uncommon mutations.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.